Identification of a novel GLA gene mutation, p.Ile239met, in fabry disease with a predominant cardiac phenotype

Beáta Csányi, Lidia Hategan, Viktória Nagy, Izabella Obál, Edina T. Varga, János Borbás, Annamária Tringer, Sabrina Eichler, T. Forster, Arndt Rolfs, Róbert Sepp

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Fabry disease (FD) is an X-linked inherited lysosomal storage disorder caused by mutations in the GLA gene, encoding for the enzyme α-galactosidase A. Although hundreds of mutations in the GLA gene have been described, many of them are variants of unknown significance. Here we report a novel GLA mutation, p.Ile239Met, identified in a large Hungarian three-generation family with FD. A 69 year-old female index patient with a clinical history of renal failure, hypertrophic cardiomyopathy, and 2nd degree AV block was screened for mutation in the GLA gene. Genetic screening identified a previously unreported heterozygous mutation in exon 5 of the GLA gene (c.717A>G; p.Ile239Met). Family screening indicated that altogether 6 family members carried the mutation (5 females, 1 male, average age: 55 ± 16 years). Three family members, including the index patient, manifested the cardiac phenotype of hypertrophic cardiomyopathy, while two other family members were diagnosed with left ventricular hypertrophy. Taking affection status as the presence of hypertrophic cardiomyopathy, left ventricular hypertrophy or elevated lyso-Gb3 levels, all affected family members carried the mutation. Linkage analysis of the family gave a two-point LOD score of 2.01 between the affection status and the p.Ile239Met GLA mutation. Lyso-Gb3 levels were elevated in all carrier family members (range: 2.4-13.8 ng/mL; upper limit of normal +2STD: ≤ 1.8 ng/mL). The GLA enzyme level was markedly reduced in the affected male family member (< 0.2 µmol/L/hour; upper limit of normal ± 2STD: ≥ 2.6 µmol/L/hour). We conclude that the p. Ile239Met GLA mutation is a pathogenic mutation for FD associated with predominant cardiac phenotype.

Original languageEnglish
Pages (from-to)454-458
Number of pages5
JournalInternational Heart Journal
Volume58
Issue number3
DOIs
Publication statusPublished - Jan 1 2017

Fingerprint

Fabry Disease
Phenotype
Mutation
Genes
Hypertrophic Cardiomyopathy
Left Ventricular Hypertrophy
Galactosidases
Atrioventricular Block
Genetic Testing
Enzymes
Renal Insufficiency
Exons

Keywords

  • Hypertrophic cardiomyopathy
  • Left ventricular hypertrophy
  • Renal failure
  • α-galactosidase A

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Csányi, B., Hategan, L., Nagy, V., Obál, I., Varga, E. T., Borbás, J., ... Sepp, R. (2017). Identification of a novel GLA gene mutation, p.Ile239met, in fabry disease with a predominant cardiac phenotype. International Heart Journal, 58(3), 454-458. https://doi.org/10.1536/ihj.16-361

Identification of a novel GLA gene mutation, p.Ile239met, in fabry disease with a predominant cardiac phenotype. / Csányi, Beáta; Hategan, Lidia; Nagy, Viktória; Obál, Izabella; Varga, Edina T.; Borbás, János; Tringer, Annamária; Eichler, Sabrina; Forster, T.; Rolfs, Arndt; Sepp, Róbert.

In: International Heart Journal, Vol. 58, No. 3, 01.01.2017, p. 454-458.

Research output: Contribution to journalArticle

Csányi, B, Hategan, L, Nagy, V, Obál, I, Varga, ET, Borbás, J, Tringer, A, Eichler, S, Forster, T, Rolfs, A & Sepp, R 2017, 'Identification of a novel GLA gene mutation, p.Ile239met, in fabry disease with a predominant cardiac phenotype', International Heart Journal, vol. 58, no. 3, pp. 454-458. https://doi.org/10.1536/ihj.16-361
Csányi, Beáta ; Hategan, Lidia ; Nagy, Viktória ; Obál, Izabella ; Varga, Edina T. ; Borbás, János ; Tringer, Annamária ; Eichler, Sabrina ; Forster, T. ; Rolfs, Arndt ; Sepp, Róbert. / Identification of a novel GLA gene mutation, p.Ile239met, in fabry disease with a predominant cardiac phenotype. In: International Heart Journal. 2017 ; Vol. 58, No. 3. pp. 454-458.
@article{2cd68b66c73b40c68208df35e4020f9a,
title = "Identification of a novel GLA gene mutation, p.Ile239met, in fabry disease with a predominant cardiac phenotype",
abstract = "Fabry disease (FD) is an X-linked inherited lysosomal storage disorder caused by mutations in the GLA gene, encoding for the enzyme α-galactosidase A. Although hundreds of mutations in the GLA gene have been described, many of them are variants of unknown significance. Here we report a novel GLA mutation, p.Ile239Met, identified in a large Hungarian three-generation family with FD. A 69 year-old female index patient with a clinical history of renal failure, hypertrophic cardiomyopathy, and 2nd degree AV block was screened for mutation in the GLA gene. Genetic screening identified a previously unreported heterozygous mutation in exon 5 of the GLA gene (c.717A>G; p.Ile239Met). Family screening indicated that altogether 6 family members carried the mutation (5 females, 1 male, average age: 55 ± 16 years). Three family members, including the index patient, manifested the cardiac phenotype of hypertrophic cardiomyopathy, while two other family members were diagnosed with left ventricular hypertrophy. Taking affection status as the presence of hypertrophic cardiomyopathy, left ventricular hypertrophy or elevated lyso-Gb3 levels, all affected family members carried the mutation. Linkage analysis of the family gave a two-point LOD score of 2.01 between the affection status and the p.Ile239Met GLA mutation. Lyso-Gb3 levels were elevated in all carrier family members (range: 2.4-13.8 ng/mL; upper limit of normal +2STD: ≤ 1.8 ng/mL). The GLA enzyme level was markedly reduced in the affected male family member (< 0.2 µmol/L/hour; upper limit of normal ± 2STD: ≥ 2.6 µmol/L/hour). We conclude that the p. Ile239Met GLA mutation is a pathogenic mutation for FD associated with predominant cardiac phenotype.",
keywords = "Hypertrophic cardiomyopathy, Left ventricular hypertrophy, Renal failure, α-galactosidase A",
author = "Be{\'a}ta Cs{\'a}nyi and Lidia Hategan and Vikt{\'o}ria Nagy and Izabella Ob{\'a}l and Varga, {Edina T.} and J{\'a}nos Borb{\'a}s and Annam{\'a}ria Tringer and Sabrina Eichler and T. Forster and Arndt Rolfs and R{\'o}bert Sepp",
year = "2017",
month = "1",
day = "1",
doi = "10.1536/ihj.16-361",
language = "English",
volume = "58",
pages = "454--458",
journal = "International Heart Journal",
issn = "1349-2365",
publisher = "International Heart Journal Association",
number = "3",

}

TY - JOUR

T1 - Identification of a novel GLA gene mutation, p.Ile239met, in fabry disease with a predominant cardiac phenotype

AU - Csányi, Beáta

AU - Hategan, Lidia

AU - Nagy, Viktória

AU - Obál, Izabella

AU - Varga, Edina T.

AU - Borbás, János

AU - Tringer, Annamária

AU - Eichler, Sabrina

AU - Forster, T.

AU - Rolfs, Arndt

AU - Sepp, Róbert

PY - 2017/1/1

Y1 - 2017/1/1

N2 - Fabry disease (FD) is an X-linked inherited lysosomal storage disorder caused by mutations in the GLA gene, encoding for the enzyme α-galactosidase A. Although hundreds of mutations in the GLA gene have been described, many of them are variants of unknown significance. Here we report a novel GLA mutation, p.Ile239Met, identified in a large Hungarian three-generation family with FD. A 69 year-old female index patient with a clinical history of renal failure, hypertrophic cardiomyopathy, and 2nd degree AV block was screened for mutation in the GLA gene. Genetic screening identified a previously unreported heterozygous mutation in exon 5 of the GLA gene (c.717A>G; p.Ile239Met). Family screening indicated that altogether 6 family members carried the mutation (5 females, 1 male, average age: 55 ± 16 years). Three family members, including the index patient, manifested the cardiac phenotype of hypertrophic cardiomyopathy, while two other family members were diagnosed with left ventricular hypertrophy. Taking affection status as the presence of hypertrophic cardiomyopathy, left ventricular hypertrophy or elevated lyso-Gb3 levels, all affected family members carried the mutation. Linkage analysis of the family gave a two-point LOD score of 2.01 between the affection status and the p.Ile239Met GLA mutation. Lyso-Gb3 levels were elevated in all carrier family members (range: 2.4-13.8 ng/mL; upper limit of normal +2STD: ≤ 1.8 ng/mL). The GLA enzyme level was markedly reduced in the affected male family member (< 0.2 µmol/L/hour; upper limit of normal ± 2STD: ≥ 2.6 µmol/L/hour). We conclude that the p. Ile239Met GLA mutation is a pathogenic mutation for FD associated with predominant cardiac phenotype.

AB - Fabry disease (FD) is an X-linked inherited lysosomal storage disorder caused by mutations in the GLA gene, encoding for the enzyme α-galactosidase A. Although hundreds of mutations in the GLA gene have been described, many of them are variants of unknown significance. Here we report a novel GLA mutation, p.Ile239Met, identified in a large Hungarian three-generation family with FD. A 69 year-old female index patient with a clinical history of renal failure, hypertrophic cardiomyopathy, and 2nd degree AV block was screened for mutation in the GLA gene. Genetic screening identified a previously unreported heterozygous mutation in exon 5 of the GLA gene (c.717A>G; p.Ile239Met). Family screening indicated that altogether 6 family members carried the mutation (5 females, 1 male, average age: 55 ± 16 years). Three family members, including the index patient, manifested the cardiac phenotype of hypertrophic cardiomyopathy, while two other family members were diagnosed with left ventricular hypertrophy. Taking affection status as the presence of hypertrophic cardiomyopathy, left ventricular hypertrophy or elevated lyso-Gb3 levels, all affected family members carried the mutation. Linkage analysis of the family gave a two-point LOD score of 2.01 between the affection status and the p.Ile239Met GLA mutation. Lyso-Gb3 levels were elevated in all carrier family members (range: 2.4-13.8 ng/mL; upper limit of normal +2STD: ≤ 1.8 ng/mL). The GLA enzyme level was markedly reduced in the affected male family member (< 0.2 µmol/L/hour; upper limit of normal ± 2STD: ≥ 2.6 µmol/L/hour). We conclude that the p. Ile239Met GLA mutation is a pathogenic mutation for FD associated with predominant cardiac phenotype.

KW - Hypertrophic cardiomyopathy

KW - Left ventricular hypertrophy

KW - Renal failure

KW - α-galactosidase A

UR - http://www.scopus.com/inward/record.url?scp=85020071256&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85020071256&partnerID=8YFLogxK

U2 - 10.1536/ihj.16-361

DO - 10.1536/ihj.16-361

M3 - Article

VL - 58

SP - 454

EP - 458

JO - International Heart Journal

JF - International Heart Journal

SN - 1349-2365

IS - 3

ER -